Hypertrophic Cardiomyopathy: What Pharmacists Need to Know in 2026
Share
Subscribe
Join us for a deep dive into hypertrophic cardiomyopathy (HCM) with Andrew Williford, PharmD, an assistant professor and cardiology specialist at UC San Diego Health. In this episode, we break down the genetics, diagnosis, and clinical impact of HCM, explore how management strategies have evolved, and discuss the emerging role of cardiac myosin inhibitors in treating obstructive disease. Dr. Williford also shares insights from his telehealth GDMT titration clinic and offers practical guidance for pharmacists encountering HCM across care settings.
Show notes:
- Hypertrophic Cardiomyopathy Guideline Hub
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
